![Vikram M. Narayan, MD(@VikramNarayan) 's Twitter Profileg](https://pbs.twimg.com/profile_images/1644881337524842496/XOp2sxD-_200x200.jpg)
Vikram M. Narayan, MD
@VikramNarayan
Urologic cancer surgeon @emory_urology & @WinshipAtEmory and Director of Urologic Oncology @GradyHealth. (Views expressed here are my own, not my employer’s.)
ID:1059456860
https://winshipcancer.emory.edu/bios/faculty/narayan-vikram 04-01-2013 03:41:53
673 Tweets
953 Followers
848 Following
Follow People
![John W. Davis, MD(@jdhdavis) 's Twitter Profile Photo John W. Davis, MD(@jdhdavis) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/3099373544/2b201bf7b9396d57cb6c7fb50e68299c_200x200.jpeg)
#AUA2024 great turnout for the MD Anderson Department of Urology alumni gathering at the Fairmont rooftop bar. #oncsurgery Brian F. Chapin
![John W. Davis, MD (@jdhdavis) on Twitter photo 2024-05-06 12:51:37 #AUA2024 great turnout for the MD Anderson Department of Urology alumni gathering at the Fairmont rooftop bar. #oncsurgery @ChapinMD #AUA2024 great turnout for the MD Anderson Department of Urology alumni gathering at the Fairmont rooftop bar. #oncsurgery @ChapinMD](https://pbs.twimg.com/media/GM5ZvaWWcAAJyVr.jpg)
![Andrea Necchi(@AndreaNecchi) 's Twitter Profile Photo Andrea Necchi(@AndreaNecchi) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1323011801211088896/ps-gwZWe_200x200.jpg)
📬 Finally out in The Lancet Oncology the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in National Comprehensive Cancer Network (NCCN) guidelines. Congrats Ashish M. Kamat, MD, MBBS Petros Grivas & team! sciencedirect.com/science/articl…
![Andrea Necchi (@AndreaNecchi) on Twitter photo 2024-05-11 06:23:09 📬 Finally out in @TheLancetOncol the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in @NCCN guidelines. Congrats @UroDocAsh @PGrivasMDPhD & team! sciencedirect.com/science/articl… 📬 Finally out in @TheLancetOncol the results from Cohort B of KN057 trial. Pembro in BCG-unresponsive papillary tumors w/out Cis. 43% 12m DFS adds a Rx piece to the literature. Now included in @NCCN guidelines. Congrats @UroDocAsh @PGrivasMDPhD & team! sciencedirect.com/science/articl…](https://pbs.twimg.com/media/GNRxMrGXMAAsgWr.jpg)
![OncLive.com(@OncLive) 's Twitter Profile Photo OncLive.com(@OncLive) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1207309207004950533/hnCTQqRs_200x200.jpg)
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…
![OncLive.com(@OncLive) 's Twitter Profile Photo OncLive.com(@OncLive) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1207309207004950533/hnCTQqRs_200x200.jpg)
The gene therapy nadofaragene firadenovec led to durable antitumor activity in a subset of patients with BCG-unresponsive NMIBC. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…
![OncLive.com (@OncLive) on Twitter photo 2024-05-08 03:00:21 The gene therapy nadofaragene firadenovec led to durable antitumor activity in a subset of patients with BCG-unresponsive NMIBC. @VikramNarayan @WinshipAtEmory #blcsm #MedTwitter #oncology onclive.com/view/nadofarag… The gene therapy nadofaragene firadenovec led to durable antitumor activity in a subset of patients with BCG-unresponsive NMIBC. @VikramNarayan @WinshipAtEmory #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…](https://pbs.twimg.com/media/GNBmAzjWEAA-yWl.jpg)
![Talia Helman(@talihelman) 's Twitter Profile Photo Talia Helman(@talihelman) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1312832640844693512/D3kfu9Sd_200x200.jpg)
![GU Oncology Now(@GUOncologyNow) 's Twitter Profile Photo GU Oncology Now(@GUOncologyNow) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1628125133885046784/uvqamROD_200x200.jpg)
🔍 In our latest video, Vikram M. Narayan, MD of Emory University, highlights research presented at #AUA24 on urinary #MRD detection for predicting recurrence and response to #nadofaragene #firadenovec in #BCG -unresponsive #NMIBC .
📚 Read More: buff.ly/3y5Ohd9
![GU Oncology Now (@GUOncologyNow) on Twitter photo 2024-05-06 20:00:26 🔍 In our latest video, @VikramNarayan of @EmoryUniversity, highlights research presented at #AUA24 on urinary #MRD detection for predicting recurrence and response to #nadofaragene #firadenovec in #BCG-unresponsive #NMIBC. 📚 Read More: buff.ly/3y5Ohd9 🔍 In our latest video, @VikramNarayan of @EmoryUniversity, highlights research presented at #AUA24 on urinary #MRD detection for predicting recurrence and response to #nadofaragene #firadenovec in #BCG-unresponsive #NMIBC. 📚 Read More: buff.ly/3y5Ohd9](https://pbs.twimg.com/media/GM68T88WMAA_6-x.jpg)
![UroToday.com(@urotoday) 's Twitter Profile Photo UroToday.com(@urotoday) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1720068505981042688/kOB1D_L0_200x200.jpg)
Efficacy of nadofaragene firadenovec-vncg for patients with BCG-unresponsive #NMIBC : Final results from a phase 3 trial. Presentation by Vikram M. Narayan, MD Emory Urology. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/4aeth10 Amer. Urol. Assn.
![UroToday.com (@urotoday) on Twitter photo 2024-05-06 18:35:22 Efficacy of nadofaragene firadenovec-vncg for patients with BCG-unresponsive #NMIBC: Final results from a phase 3 trial. Presentation by @VikramNarayan @emory_urology. #AUA24 written coverage by @chavarriagaj @UofT > bit.ly/4aeth10 @AmerUrological Efficacy of nadofaragene firadenovec-vncg for patients with BCG-unresponsive #NMIBC: Final results from a phase 3 trial. Presentation by @VikramNarayan @emory_urology. #AUA24 written coverage by @chavarriagaj @UofT > bit.ly/4aeth10 @AmerUrological](https://pbs.twimg.com/media/GM6o0sCWYAA9Fyu.png)
![Journal of Urology(@JUrology) 's Twitter Profile Photo Journal of Urology(@JUrology) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1486157301484556291/BpG1__4l_200x200.jpg)
![Zach Klaassen(@zklaassen_md) 's Twitter Profile Photo Zach Klaassen(@zklaassen_md) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1002653689025384454/pjbPMtmQ_200x200.jpg)
#AUA24 Sima Porten IBCG
Bladder Preserving Options currently available (BCG unresponsive)
UroToday.com
![Zach Klaassen (@zklaassen_md) on Twitter photo 2024-05-05 20:48:53 #AUA24 @SimaPorten @IBCG_BladderCA Bladder Preserving Options currently available (BCG unresponsive) @urotoday #AUA24 @SimaPorten @IBCG_BladderCA Bladder Preserving Options currently available (BCG unresponsive) @urotoday](https://pbs.twimg.com/media/GM19zq-WMAAaUWF.jpg)
![Vikram M. Narayan, MD(@VikramNarayan) 's Twitter Profile Photo Vikram M. Narayan, MD(@VikramNarayan) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1644881337524842496/XOp2sxD-_200x200.jpg)
Congratulations to Talia Helman representing Emory Urology with fantastic double hitter BPH presentations on surgical therapy and new technology Brendan Browne
![Vikram M. Narayan, MD (@VikramNarayan) on Twitter photo 2024-05-05 21:48:51 Congratulations to @talihelman representing @emory_urology with fantastic double hitter BPH presentations on surgical therapy and new technology @BBrowne17071 Congratulations to @talihelman representing @emory_urology with fantastic double hitter BPH presentations on surgical therapy and new technology @BBrowne17071](https://pbs.twimg.com/media/GM2Lh-MWMAAz4g-.jpg)
![OncLive.com(@OncLive) 's Twitter Profile Photo OncLive.com(@OncLive) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1207309207004950533/hnCTQqRs_200x200.jpg)
Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC Vikram M. Narayan, MD Winship Cancer Institute of Emory University Emory Urology Amer. Urol. Assn. #AUA24 #AUA2024 #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…
![Julian Chavarriaga(@chavarriagaj) 's Twitter Profile Photo Julian Chavarriaga(@chavarriagaj) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1495549045900779525/8pYoAeyp_200x200.jpg)
![Urology Times(@UrologyTimes) 's Twitter Profile Photo Urology Times(@UrologyTimes) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1428226899055161344/MpzhA905_200x200.jpg)
“At 60 months, nadofaragene allowed bladder preservation in nearly half of the patients in the CIS cohort and two-thirds of patients in the Ta/T1 cohort,” said Vikram Narayan, MD. #AUA24 #bladdercancer Vikram M. Narayan, MD
urologytimes.com/view/nadofarag…
![Targeted Oncology(@TargetedOnc) 's Twitter Profile Photo Targeted Oncology(@TargetedOnc) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1613990098751655968/dd4_a3Cs_200x200.jpg)
Five-year data from a trial confirms gene therapy nadofaragene firadenovec remains effective against aggressive bladder cancer. #AUA24 #AUA2024 #BLCSM | Vikram M. Narayan, MD Emory Urology Winship Cancer Institute of Emory University
targetedonc.com/view/5-year-da…
![D. Delattre, MD, PhD(@DrDelattre) 's Twitter Profile Photo D. Delattre, MD, PhD(@DrDelattre) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1310520522271346689/fIo-NYnW_200x200.jpg)
#AUA24 Podium presentation Efficacy of Nadofaragene Firadenovec for Patients BCG Unresponsive NMIBC Final Results
Vikram M. Narayan, MD Stephen Boorjian, MD @Colin Dinney@study investigators
At 60M nadofaragene allowed bladder preservation in half of patients in CIS & two-thirds in Ta/T1 cohorts
![D. Delattre, MD, PhD (@DrDelattre) on Twitter photo 2024-05-05 18:29:40 #AUA24 Podium presentation Efficacy of Nadofaragene Firadenovec for Patients BCG Unresponsive NMIBC Final Results @VikramNarayan @SBoorjian @Colin Dinney@study investigators At 60M nadofaragene allowed bladder preservation in half of patients in CIS & two-thirds in Ta/T1 cohorts #AUA24 Podium presentation Efficacy of Nadofaragene Firadenovec for Patients BCG Unresponsive NMIBC Final Results @VikramNarayan @SBoorjian @Colin Dinney@study investigators At 60M nadofaragene allowed bladder preservation in half of patients in CIS & two-thirds in Ta/T1 cohorts](https://pbs.twimg.com/media/GM1d7cKWQAA19em.jpg)
![Stephen B. Williams, MD, MBA, MS, FACHE(@SWilliams_MD) 's Twitter Profile Photo Stephen B. Williams, MD, MBA, MS, FACHE(@SWilliams_MD) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1765171088751742976/ZvSZHRxO_200x200.jpg)
Excited to present this work at #AUA24 and UTMBUrology being a lead center to provide the data, collaboration, and deploy Valar Labs early access to determine the value stream to our patients. 🎉🙏UTMBPresident UTMB Provost's Office UTMB Health IBCN IBCG Amer. Urol. Assn.